{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:10:12Z","timestamp":1785906612717,"version":"3.56.0"},"reference-count":67,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH107-7M11"],"award-info":[{"award-number":["KMUH107-7M11"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH108-8M12"],"award-info":[{"award-number":["KMUH108-8M12"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 110-2314-B-037-083"],"award-info":[{"award-number":["MOST 110-2314-B-037-083"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Considering a steady increase in the number of allogeneic hematopoietic stem cell transplantations (allo-HSCT) worldwide and the significant proportion of the world\u2019s population that has been exposed to hepatitis B virus (HBV) infection, HBV reactivation following allo-HSCT remains an important issue for post-transplant morbidity and mortality. Antiviral prophylaxis can reduce HBV replication, severity of HBV-related hepatitis, and mortality; therefore, identification of patients at risk is crucial. It is recommended that all recipients and donors should be screened for active or prior HBV infection, including HBsAg, antiHBc, and antiHBs. Adoptive immunity transfer from the donor seems to have protective effects against HBV reactivation. Antiviral prophylaxis should be initiated in all HBsAg-positive patients. HBsAg-negative, antiHBc-positive patients remain at risk; therefore, antiviral prophylaxis should be considered if baseline serum HBV DNA is detectable. In HBsAg-negative, antiHBc-positive patients without detectable HBV DNA, close monitoring of viral load with an on-demand therapy is necessary. Entecavir or tenofovir rather than lamivudine are more appropriate for the emergence of lamivudine resistance. The treatment duration remains unclear, with 6- to 12-month therapy after cessation of immunosuppressive therapy commonly recommended. Here we review the updated evidence and recent recommendations regarding HBV reactivation in patients undergoing allo-HSCT for individualized therapy.<\/jats:p>","DOI":"10.3390\/jpm11111108","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T23:51:36Z","timestamp":1635465096000},"page":"1108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.3390","volume":"11","author":[{"given":"Yi-Chang","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"},{"name":"Cellular Therapy and Research Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-6022","authenticated-orcid":false,"given":"Chi-Mu","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Yien","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rutgers-Camden, Camden, NJ 08102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-1045","authenticated-orcid":false,"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"},{"name":"Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10096-015-2341-x","article-title":"Prevention of hepatitis B virus infection: From the past to the future","volume":"34","author":"Orlando","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?","volume":"61","author":"Lok","year":"2015","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1586\/eri.11.105","article-title":"Hepatitis B virus infection: Pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients","volume":"9","author":"Moses","year":"2011","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cgh.2013.04.036","article-title":"Management of hepatitis B: Our practice and how it relates to the guidelines","volume":"12","author":"Yapali","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: A global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current Use and Trends in Hematopoietic Cell Transplantation in the United States","volume":"23","author":"Lee","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","article-title":"Allogeneic hematopoietic cell transplantation; the current renaissance","volume":"34","author":"Copelan","year":"2019","journal-title":"Blood Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1665-2681(19)30778-1","article-title":"Prospective study of hepatitis B virus reactivation in patients with hematological malignancies","volume":"14","author":"Pompili","year":"2015","journal-title":"Ann. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gentile, G., and Antonelli, G. (2019). HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses, 11.","DOI":"10.3390\/v11111049"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"610500","DOI":"10.3389\/fimmu.2020.610500","article-title":"Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"O694","DOI":"10.1111\/1469-0691.12611","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: Risk factors and outcome","volume":"20","author":"Mikulska","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.510250631","article-title":"Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer","volume":"25","author":"Lau","year":"1997","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B Virus Screening for Patients with Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update","volume":"33","author":"Hwang","year":"2015","journal-title":"J Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"#cr-split#-ref_18.1","unstructured":"European Association for the Study of the Liver (2017). Electronic address, e. e. e."},{"key":"#cr-split#-ref_18.2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the, L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370-398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis","volume":"164","author":"Paul","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hu, J., Protzer, U., and Siddiqui, A. (2019). Revisiting Hepatitis B Virus: Challenges of Curative Therapies. J. Virol., 93.","DOI":"10.1128\/JVI.01032-19"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12072-008-9056-3","article-title":"Hepatitis B reactivation after chemotherapy: Two decades of clinical research","volume":"2","author":"Lau","year":"2008","journal-title":"Hepatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2011.4","article-title":"Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy","volume":"104","author":"Yun","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S778","DOI":"10.1093\/infdis\/jix178","article-title":"Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy","volume":"216","author":"Choi","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V96.2.452.014k13_452_458","article-title":"A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation","volume":"96","author":"Lau","year":"2000","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1600-6143.2005.00887.x","article-title":"Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors","volume":"5","author":"Hui","year":"2005","journal-title":"Am. J. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1399-3062.2012.00732.x","article-title":"No increased mortality from donor or recipient hepatitis B- and\/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation","volume":"14","author":"Tomblyn","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.bbmt.2011.04.006","article-title":"Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus","volume":"17","author":"Park","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.15884","article-title":"Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world\u2019s largest retrospective cohort study","volume":"186","author":"Liu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2015.328","article-title":"A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: A single-institutional experience","volume":"51","author":"Shang","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2005-02-0698","article-title":"A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"106","author":"Hui","year":"2005","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","article-title":"Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab","volume":"78","author":"Moses","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jmv.21995","article-title":"Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy","volume":"83","author":"Sugauchi","year":"2011","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbmt.2009.12.532","article-title":"Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Ramos","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2010.70","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","author":"Vigano","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.29022","article-title":"Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study","volume":"65","author":"Seto","year":"2017","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s10620-019-05614-6","article-title":"Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B","volume":"64","author":"Lee","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41409-018-0355-6","article-title":"HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: A 12-year experience at a single center","volume":"54","author":"Bae","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2020.01.006","article-title":"Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative\/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation","volume":"26","author":"Zhang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2008-10-163493","article-title":"How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang","year":"2009","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4254\/wjh.v6.i5.284","article-title":"Chronic hepatitis B: Advances in treatment","volume":"6","author":"Santantonio","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.3748\/wjg.v21.i14.4284","article-title":"Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients","volume":"21","author":"Liao","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","article-title":"Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: A systematic review","volume":"23","author":"Gentile","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.bbmt.2009.03.024","article-title":"Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation","volume":"15","author":"Le","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/tid.12283","article-title":"Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: Long-term analysis of intervention in RS with vaccine for patients with previous HBV infection","volume":"16","author":"Takahata","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41409-020-0833-5","article-title":"A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation","volume":"55","author":"Nishikawa","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e14024","DOI":"10.1111\/ctr.14024","article-title":"Immune responses to hepatitis B vaccination after hematopoietic stem cell transplantation in pediatric and young adult patients","volume":"34","author":"Chaichotjinda","year":"2020","journal-title":"Clin Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2020.05.006","article-title":"Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation","volume":"26","author":"Conrad","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/bmt.2015.253","article-title":"Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors","volume":"51","author":"Lindemann","year":"2016","journal-title":"Bone Marrow Transplant."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:11Z","timestamp":1760167331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/11\/1108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":67,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jpm11111108"],"URL":"https:\/\/doi.org\/10.3390\/jpm11111108","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}